Prostanozol — demethylstanozolol tetrahydropyranyl

Prostanozol (demethylstanozolol THP) is an oral anabolic steroid closely related to Winstrol (stanozolol) in structure. It differs from stanozolol only by the removal of the c-17 alpha alkyl group, which undoubtedly hurts the oral bioavailability of this steroid. In an attempt to compensate for this, an ether group has been added. The ether increases oil solubility and the likelihood of lymphatic delivery with dietary fats, which bypass the first pass through the liver. This is the same principle on- which Anabolicum Vister (quinbolone) was developed. In the case of Prostanozol, however, there is no oil carrier, which significantly lowers the chance for lymphatic delivery.This will necessitate a much higher oral dosage than would be needed otherwise. Among athletes, the drug is valued as,a non-liver-toxic oral anabolic with properties qualitatively (although not quantitatively) similar to those of stanozolol.

Brand name Prostanozol, Demethylstanozolol tetrahydropyranyl
Androgenic no data available
Anabolic no data available
Standard no data available
Chemical Names 17beta-Hydroxy-5alpha-androstano
Estrogenic Activity none
Progestational Activity no data available

Prostanozol History

Demethylstanozolol appears to be a new chemical entity. If a non-methylated stanozolol were synthesized and assayed in the past, it could not be located.This steroid was introduced to the U.S. sports nutrition market in 2005 as a "post-ban" hormone, distributed openly as a "dietary supplement" instead of being regulated as a prescription drug. This is stemming from the fact that it was unknown to lawmakers at the time the 1991 and 2004 anabolic steroid laws were enacted, and as such simply could not be included in them. Although its legal status as a nutritional supplement may be in question (it is technically not found in the food supply, and therefore not a dietary food supplement), there are no U.S. criminal laws against its possession or use (yet).

Prostanozol is one of several legitimate synthetic anabolic/androgenic steroid products that hit the market in 2005. Later that year, however, the FDA and others in the government angrily acknowledged that there were new "designer steroids" on the supplement market, and made clear their intentions on investigating and even prosecuting those misbranding steroid products (drugs) as supplements. The original manufacturer (ALRI) quickly discontinued the sale of Prostanozol, anticipating FDA action. Other versions, such as Orastane-E by Gaspari Nutrition, have been discontinued as well. Given the threats of prosecution, it is unlikely that a major supplement manufacturer will risk introducing demethylstanozolol to market again. As such, this likely ended the commercial availability of this steroid.

How is Prostanozol Supplied

Demethylstanozolol is not available as a prescription drug product. When produced in the U.S. as a dietary supplement, it came In the form of a 25 mg capsule.

Structural Characteristics of Prostanozol

Demethylstanozolol is a modified form of dihydrotestosterone. It differs by the attachment of a pyrazol group to the A ring, replacing the normal 3-keto group (this gives demethylstanozolol the chemical classification of a heterocyclic steroid). Prostanozol contains demethylstanozolol with an ether (tetrahydropyranyl) attached to the 17-beta hydroxyl group, which slightly increases its oral bioavailability by facilitating absorption via the lymphatic route.

Prostanozol Side Effects (Estrogenic)

Demethylstanozolol is not aromatized by the body, and is not measurably estrogenic. An anti-estrogen is not necessary when using this steroid, as gynecomastia should not be a concern even among sensitive individuals. Since estrogen is the usual culprit with water retention, this steroid instead produces a lean, quality look to the physique with no fear of excess subcutaneous fluid retention. This makes it a favorable steroid to use during cutting cycles, when water and fat retention are major concerns.

Prostanozol Side Effects (Androgenic)

Although classified as an anabolic steroid, androgenic side effects are still common with this substance. This may include bouts of oily skin, acne, and body/facial hair growth. Anabolic/androgenic steroids may also aggravate male pattern hair loss. Women are also warned of the potential virilizing effects of anabolic/androgenic steroids. These may include a deepening of the voice, menstrual irregularities, changes in skin texture, facial hair growth,and clitoral enlargement. Additionally, the 5-alpha reductase enzyme does not metabolize demethylstanozolol, so its relative androgenicity is not affected by finasterfde or dutasteride. Note that this steroid is relatively mild as an androgen, and much less likely to produce androgenic side effects than therapy with testosterone, methandrostenolone, or fluoxymesterone.

Prostanozol Side Effects (Hepatotoxicity)

Demethylstanozolol is not a cl 7-alpha alkylated compound, and is not known to have hepatotoxic effects; liker toxicity is unlikely.

Prostanozol Side Effects (Cardiovascular)

Anabolic/androgenic steroids can have deleterious effects on serum cholesterol. This includes a tendency to reduce HDL (good) cholesterol values and increase LDL (bad) cholesterol values, which may shift the HDL to LDL balance in a direction that favors greater risk of arteriosclerosis. The relative impact of an anabolic/androgenic steroid on serum lipids is dependant on the dose, route of administration (oral vs. injectable), type of steroid (aromatizable or non-aromatizable), and level of resistance to hepatic metabolism. Demethylstanozolol should have a stronger effect on the hepatic management of cholesterol than testosterone or nandrolone due to its non-aromatizable nature and route of administration. Anabolic/androgenic steroids may also adversely affect blood pressure and triglycerides, reduce endothelial relaxation, and support left ventricular hypertrophy, all potentially increasing the risk of cardiovascular disease and myocardial infarction.

To help reduce cardiovascular strain it is advised to maintain an active cardiovascular exercise program and minimize the intake of saturated fats, cholesterol, and simple carbohydrates at all times during active AAS administration. Supplementing with fish oils (4 grams per day) and a natural cholesterol/antioxidant formula such as Lipid Stabil or a product with comparable ingredients is also recommended.

Prostanozol Side Effects (Testosterone Suppression)

All anabolic/androgenic steroids when taken in doses sufficient to promote muscle gain are expected to suppress endogenous testosterone production. Without the intervention of testosterone-stimulating substances, testosterone levels should return to normal within 1-4 months of drug secession. Note that prolonged hypogonadotrophic hypogonadism can develop secondary to steroid abuse, necessitating medical intervention.

Prostanozol Administration (Men)

Demethylstanozolol was never approved for use in humans. Prescribing guidelines are unavailable. An effective dosage for physique- or performance-enhancing purposes seems to begin in the range of 100 mg-150 mg per day, taken for 6-8 weeks. This level seems to impart a decent effect on lean tissue gain and strength, although higher doses would be needed for a very strong anabolic effect.

Prostanozol Administration (Women)

Demethylstanozolol was never approved for use in humans. Prescribing guidelines are unavailable. An effective dosage for physique- or performance-enhancing purposes seems to be 25 mg per day, taken for no longer than 4-6 weeks. For most users, this level seems to impart a decent effect on lean tissue gain and strength without side effects. Higher doses would increase the likelihood of virilizing effects, however, and should be carefully monitored.

Prostanozol Availability

Demethylstanozolol was never produced as a prescription drug product. It may still be found as an underground steroid.


Wlliam Llewellyn (2017) - Anabolics

Your experience with Prostanozol — demethylstanozolol tetrahydropyranyl

There are no comments yet.